Accordingly, understanding the mechanisms of ZIP7 action in the context of IR may provide opportunities to develop novel therapeutic options to target this transporter in the treatment of IR and subsequent T2DM. The gene discussed is SLC39A7; the disease is type 2 diabetes mellitus.